Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025
The company’s virgin PET chips plant in Egypt, commissioned in Q4 FY25, achieved 74.8 per cent capacity utilization in its first full quarter. In India, the Panipat facility operated at 96.6 per cent utilization
The new facility will enhance AbbVie’s chemical synthesis capacity to support domestic production of current and next-generation neuroscience, immunology, and oncology medicines
Rivaroxaban is used to treat venous thromboembolism
AINU is set to accelerate its expansion footprint, enhance operational capabilities
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Norepinephrine Bitartratein 5% Dextrose of Baxter Healthcare Corp
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
With this addition, the company’s total Installed MCC Capacity will rise to 30,000 MTPA
Subscribe To Our Newsletter & Stay Updated
